Immunosuppression as a possible risk factor for interferon non-response in ocular surface squamous neoplasia
| Autor: | Noy Ashkenazy, Gaofeng Wang, Anat Galor, Carolina Mercado Acosta, Carol L. Karp |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Conjunctival Neoplasm
Male medicine.medical_specialty Antimetabolites Antineoplastic medicine.medical_treatment Administration Topical Alpha interferon Conjunctival Neoplasms Interferon alpha-2 Eye neoplasm Article Corneal Diseases 03 medical and health sciences Immunocompromised Host 0302 clinical medicine Risk Factors Carcinoma medicine Humans Immunologic Factors Treatment Failure Risk factor Aged Retrospective Studies Immunosuppression Therapy Chemotherapy business.industry Eye Neoplasms Interferon-alpha Immunosuppression Retrospective cohort study medicine.disease Dermatology Recombinant Proteins Ophthalmology 030220 oncology & carcinogenesis Immunology 030221 ophthalmology & optometry Carcinoma Squamous Cell Fluorouracil Ophthalmic Solutions business |
| Popis: | Purpose The mechanism by which ocular surface squamous neoplasia (OSSN) responds to topical interferon-alpha-2b (IFNα2b) is not known. We report the cases of 3 immunosuppressed patients whose tumors did not respond to topical IFNα2b therapy. The purpose of this series is to shed light on potential mechanisms of IFNα2b in OSSN. Methods Retrospective case series of 3 immunosuppressed patients whose biopsy-proven OSSN did not respond to topical IFNα2b treatment. Results Three white, immunosuppressed males (mean age 70 years, range 66-76) were diagnosed with OSSN. Topical IFNα2b 1 million units/mL was administered 4 times a day and used for a mean of 5 months (range 2-7 mo) without an adequate response. All patients were then switched to 5-fluorouracil. Successful eradication of OSSN was achieved in 2 cases, and improvement of OSSN in another. The latter patient was switched to mitomycin-C with subsequent resolution of OSSN. Conclusions These cases suggest that an intact immune system may be an important link between IFNα2b therapy and tumor resolution. As such, topical IFNα2b may not be an optimal choice for patients with underlying immunosuppression. It may be more effective in this patient population to switch to a non-immune-modulating therapy such as 5-fluorouracil or mitomycin-C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|